Dr. Angela Ruban's team at Tel Aviv University has cracked a problem that has stumped neuroscientists for decades: how to stop the cascade of damage that continues long after a spinal cord injury occurs. The results, published in Inflammation and Regeneration, are startling—treated animals recovered up to 80% of their normal walking and movement abilities within two months, compared to just 30% in untreated groups.
The real tragedy of spinal cord injury lies not in the initial blow, but in what happens next. Within minutes of trauma, a neurochemical called glutamate floods the injury site, poisoning nerve cells and triggering inflammation that spreads the damage far beyond the original wound. This secondary cascade—for which no FDA or EMA-approved treatment yet exists—is what typically leads to permanent disability. The spinal cord essentially injures itself further as the body's own chemistry turns against it.
The breakthrough comes from a deceptively simple idea: instead of trying to block glutamate's harmful effects in the brain itself, Dr. Ruban and her colleagues, working with students Josef Levin, Rosemary Lavender, Alexander Yakovchuk, Evgeny Banyas, and Ruth Baltovska, found a way to remove excess glutamate directly from the bloodstream. The treatment, administered as an intravenous injection in the first hours after injury, dramatically reduced glutamate levels in animal models, minimizing inflammation and nerve cell death while preserving the delicate architecture of neural tissue—the axons and synapses that allow movement and sensation.
What makes this especially promising for real-world medicine is the eight-hour therapeutic window. This isn't a treatment that requires immediate access to a specialized hospital center; it can be administered by first responders in the field, potentially halting the damage cascade before it spirals out of control. In emergency situations—on a battlefield, at the scene of an accident—that window could mean the difference between walking again and lifelong paralysis.
Dr. Ruban emphasizes that the significance reaches beyond the impressive motor recovery rates. "The importance of the study is not only the functional improvement, but the very ability to impact secondary damage—for which no effective treatments have been discovered so far," she explains. The research suggests a potential to prevent the chain reaction that typically aggravates patients' conditions, preserving neural functions that would otherwise be lost forever. If the approach proves effective in humans, it would represent a fundamental shift from merely managing spinal cord injury to actually preventing the extent of the damage.
The implications extend well beyond spinal cord injuries. Dr. Yona Goldshmit notes that this method could revolutionize treatment for other traumatic brain injuries caused by stroke or trauma, enabling far more successful rehabilitation by reducing the neural damage patients face in the first place. The researchers are now collaborating with Israel's Ministry of Defense and TAU Professor Chaim Pick to test the treatment in blast-induced head injury models—a grim but relevant research direction given recent global conflicts and their neurological toll.
These early results in animal models offer genuine hope to the millions worldwide living with spinal cord injury. If human trials confirm what the mice are telling us, this simple intravenous approach could transform neurotrama from a condition of managed decline into one of active recovery.